Eli Lilly and Company price

R$5,882.89R$0.00 (--)
Last updated on 9 Oct 2026, 04:32:20.
Market cap
R$5.42T
Circulating supply
--
All-time high
R$6,507.43
24h volume
R$243.58K

About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Stock ticker
LLY
Company
Eli Lilly and Company
Industry
Healthcare
Category
US
Stock split / reverse split
12
Launch date
1 June 1972
Listed exchange
NYSE

Financials

Q2 FY2026 Earnings
Report period: 1 Apr 2026 – 30 June 2026

Summary: LLY reported Revenue of 22.97B (+47.67%), beating expectations; EPS of 8.38 (+32.81%), beating expectations.

Revenue (USD)Beat22.97B+47.66%20.82B+41.61%2.15B+10.33%
EPS (USD)Beat8.38+32.80%6.40+14.28%1.98+30.93%
Financial estimates
● Actual● Estimate
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
6.296.217.398.267.94
+91.76%+480.37%+51.43%+169.93%+26.23%
● EPS● YoY
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
100.92B114.94B112.48B116.58B142.28B
82.57B91.08B85.94B85.38B108.40B
81.81%79.24%76.40%73.23%76.18%
● Assets● Liabilities● Ratio
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
3.09B8.84B3.22B5.33B10.69B
+110.53%+138.04%+30.35%+220.18%+246.30%
● CFO● YoY

Shareholders

Shareholders
LILLY ENDOWMENT INC10.12%
BLACKROCK, INC.7.56%
VANGUARD CAPITAL MANAGEMENT LLC5.99%
PNC FINANCIAL SERVICES GROUP, INC.5.75%
STATE STREET CORP4.04%
Others66.50%
Institutions
% Owned88.91%+2.11%
Shares held793.44M+17.03M
Institutions4,795+277
% OwnedPrice
Name% OwnedChange
LILLY ENDOWMENT INC10.12%-1.52M
BLACKROCK, INC.7.56%+1.16M
VANGUARD CAPITAL MANAGEMENT LLC5.99%+167.09K
PNC FINANCIAL SERVICES GROUP, INC.5.75%-6.19K
STATE STREET CORP4.04%+605.75K

Dividends

Dividends
Last ex-dividend: 14 Aug 2026 Cash dividend: 1.73 USD per share
Dividend yield TTM
0.58%
Payout ratio LFY
26.14%
Frequency
Quarterly
20222023202420252026
3.924.525.206.005.19
+1.10%+0.73%+0.69%+0.58%+0.56%
Dividend amount (USD)Dividend yield
Stock splits
Launch date: 1 June 1972
DateRatio
16 Oct 19971 → 2
21 Dec 19951 → 2
1 May 19891 → 2
30 Jan 19861 → 2
Trade on the go with the OKX app

Eli Lilly and Company’s recent prices

Past year----
3 months----
30 days+3.40%R$5,689.29
7 days+2.41%R$5,744.38

Eli Lilly and Company performance

R$5,882.89
Eli Lilly and Company price today

Eli Lilly and Company price today is R$5,882.89, marking a -- over the past 24 hours. On OKX, today’s Eli Lilly and Company trading volume reached 41.00, worth over R$243,579.36.

R$6,507.43
Eli Lilly and Company all-time high

Eli Lilly and Company achieved its all-time high price of R$6,507.43 on 19 Aug 2026. At today’s price of R$5,882.89, Eli Lilly and Company price is now -9.60% lower than its historic high.

$1,168.40
Eli Lilly and Company in USD

The current Eli Lilly and Company to USD conversion rate is $1,168.40 per Eli Lilly and Company.

Guides

Find out how to buy Eli Lilly and Company

Getting started with crypto can feel overwhelming, but learning where and how to buy crypto is simpler than you might think. Kickstart your journey on the OKX mobile app, or right here on the web.

Dive in

Predict Eli Lilly and Company’s prices

How much will Eli Lilly and Company be worth over the next few years? Check out the community’s thoughts and make your predictions.

Forecast

View Eli Lilly and Company’s price history

Track your Eli Lilly and Company’s price history to monitor your holdings’ performance over time. You can easily view the open and close values, highs, lows, and trading volume using the table below.

Check it out

More to explore

Eli Lilly and Company FAQ

Eli Lilly and Company can offer strong returns, but is also subject to market volatility. Whether it’s a good investment depends on your risk tolerance, goals, and market conditions. Eli Lilly and Company’s price can be influenced by various factors such as adoption, regulation, technological advancement, and overall market sentiment. Always do your own research before buying Eli Lilly and Company and never buy more than you can afford to lose. This content is for informational purposes only and isn’t financial advice.

To buy Eli Lilly and Company at a low price, monitor the market closely and use tools like price alerts and technical indicators to keep you updated on price trends. Always do your own research and use secure platforms. This content is for informational purposes only and isn’t financial advice.

Depending on where you’re located, you can use bank transfer, credit/debit card, or Peer-to-Peer. Read our guide on how to use these different payment methods to buy Eli Lilly and Company xLLY safely on a trusted exchange like OKX.

Currently, one Eli Lilly and Company is worth 1168.4. For answers and insight into Eli Lilly and Company’s price action, you’re in the right place. Explore the latest Eli Lilly and Company charts and trade responsibly with OKX.

To read this Eli Lilly and Company price chart, hover over or click on the time period you want to view. Hover over the chart to view the corresponding price, displayed in your local currency.

Yes, Eli Lilly and Company’s price is updated in real-time on our Eli Lilly and Company price page. You can view the current price and historical price data here at all times.

Countries and regions differ on how digital assets transactions and holdings are taxed and how they view digital assets in general (money, property, commodity). In general, it is expected that you will pay capital gains tax when selling or swapping Eli Lilly and Company xLLY. Refer here for a more detailed guide.

Staking and earning rewards with Eli Lilly and Company are subject to local restrictions. Log in or sign up to view products available in your country, region, or state of residence.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.